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Introduction
Primary biliary cirrhosis (PBC) is a chronic, slowly
progressive, cholestatic, autoimmune disease of the
liver.1,2 It is characterized by fatigue, pruritus and 
the presence of antimitochondrial antibody (AMA).3
Histologically, PBC causes portal inflammation and
destruction of the small intrahepatic bile ducts through
an immune-mediated mechanism.1 It affects predom-
inantly middle-aged women.1–4 The ratio of women to
men is around 10 to 1.1 The clinical manifestations,
progression and prognosis of PBC are quite diverse.1–4
Some patients remain asymptomatic decades after
diagnosis, while others progress to end-stage liver dis-
ease rapidly in spite of ursodeoxycholic acid (UDCA)
therapy.4,5 Hepatocellular carcinoma (HCC) has been
reported in some patients with PBC.6–15 The tumors
occurred in the late stage of PBC in the majority of
cases and were seldom diagnosed in the asymptomatic
stage.10–12,15 Hence, except for liver transplantation,
such patients rarely underwent curative therapies such
as resection surgery or local ablation therapy and were
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RFA of HCC in PBC patient with anti-HBc
associated with dismal outcomes.13 It may be due to
poor liver reserve in the late stage of PBC when HCC
was diagnosed. Herein, we report a case of successful
radiofrequency ablation (RFA) therapy of HCC in a
66-year-old male patient with PBC.
Case Report
A 66-year-old man had suffered from intermittent
pruritus for 8 years. But he had not experienced yel-
lowish discoloration of the skin or tea-colored urine
in that period. He denied any history of blood trans-
fusion, acupuncture, tattoo, herbal medicine, smoking
or alcohol drinking.
He underwent physical check-up in September
2005, and a diagnosis of PBC was established after a
series of examinations. Serum biochemistry tests showed
alanine aminotransferase (ALT) level of 86 U/L (nor-
mal, 0–40U/L), aspartase aminotransferase (AST) level
of 92 U/L (normal, 5–45 U/L), alkaline phosphatase
(ALK-P) level of 229U/L (normal, 10–100U/L), total
bilirubin level of 0.9mg/dL (normal, 0.2–1.6mg/dL),
γ-glutamyltransferase (GGT) level of 630 U/L (nor-
mal, 8–61 U/L), albumin level of 4.5 g/dL (normal,
3.7–5.3 g/dL), immunoglobulin G (IgG) level of
2,270mg/dL (normal, 1,188–1,800mg/dL), IgA level
of 309 mg/dL (normal, 158–358 mg/dL) and IgM
level of 138 mg/dL (normal, 72–216 mg/dL).
Serologic tests for hepatitis B surface antigen
(HBsAg), antibody to hepatitis B surface antigen (anti-
HBs), and antibody to hepatitis C virus (anti-HCV)
were all negative. But antibody against hepatitis B
core antigen (anti-HBc) was positive, indicating a
previous or occult hepatitis B virus (HBV) infection.
Serum HBV DNA was negative by polymerase chain
reaction method. Serum autoantibodies including anti-
nuclear antibody and anti-smooth muscle antibody
were negative, but AMA (Fluoro-kit; Incstar, Stillwater,
MN, USA) was positive. The patient refused to receive
liver biopsy at that time and UDCA at a dosage 
of 200 mg thrice a day was prescribed based on the
diagnosis of probable PBC.1 Serum ALK-P level grad-
ually declined, with levels of 118 U/L and 108 U/L
after 5 months and 8 months of UDCA therapy,
respectively.
In February 2007, a relatively hypoechoic nodule,
measuring 2.6 cm in diameter, with nodule-in-nodule
appearance and a hypoechoic halo in segment V of
the liver, was found by routine abdominal ultrasound
examination. Dynamic computed tomography (CT)
examinations revealed 1 hypodense nodular lesion with
faint contrast enhancement in the arterial phase and
rapid washout in the portal venous phase in the same
segment (Figure 1). Serum α-fetoprotein (AFP) level
was 189 ng/mL (normal, < 8.50 ng/mL).
Liver biopsy was performed and 2 specimens were
taken from the tumor part and non-tumor part, respec-
tively. Non-tumorous liver revealed focal destruction
of bile duct epithelium with lymphocyte infiltration,
and focal absence of bile duct combined with periportal
fibrosis and necrosis (Figure 2). The aforementioned
findings were compatible with Scheuer’s classification
of stage II PBC.4 Moreover, HBcAg stain and HBsAg
stain were both negative. The tumor part showed 
a moderately differentiated HCC in a trabecular and
acinar pattern (Figure 3). So the patient underwent
percutaneous RFA. The course was smooth with no
specific complications. One month after RFA, no viable
tumor was found by CT examination (Figure 4).
A B
Figure 1. Abdominal computed tomography shows a nodular lesion, 2.6 cm in diameter, in segment V of the liver, with: (A) faint contrast
enhancement in the early arterial phase (arrow); and (B) rapid washout in the portal venous phase (arrowhead).
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Discussion
The diagnosis of PBC is established based on the follow-
ing 3 criteria: elevation of serum ALK-P, the presence
of detectable AMA in serum, and characteristic his-
tologic findings including asymmetric destruction of
the bile ducts within the portal triads.1 A probable
diagnosis requires that 2 of the 3 criteria are met, and
a definite diagnosis requires that all 3 criteria are
met.1 This patient responded well to UDCA and serum
ALK-P level declined gradually after therapy. Although
the patient did not receive liver biopsy at the time 
of diagnosis, the clinical findings and clinical course,
response to UDCA therapy and the subsequent liver
biopsy all support a definite diagnosis of PBC.
The relationship between PBC and HCC was
obscure until recently. In earlier years, patients with
PBC were considered to be at relatively low risk for
HCC in comparison to cirrhosis from other etiolo-
gies.9,10 It was assumed that the dominance of the
female population and some patients being enrolled
while in the early stage of PBC may explain this phe-
nomenon.10 HCC usually occurs in the late stage of
PBC, so patients cannot undergo curative therapy due
to the deterioration of liver reserve, which in turn leads
to a dismal prognosis.8,12 As more frequent screening
of AMA in suspected cases occurs, patients with PBC
are now more likely to be diagnosed when asymptom-
atic or when in an earlier stage than in the past.1 The
majority of patients with PBC are treated with
UDCA, and excellent long-term survival was observed
in those with good biochemical response to UDCA.5
Moreover, these patients receive more strict tumor
surveillance in the present era. All of these efforts have
led to the discovery of more cases of HCC arising
from PBC. In addition, several studies have evaluated
A B
Figure 2. The non-cancerous liver specimen shows focal destruction of bile duct epithelium with lymphocyte infiltration, focal absence
of bile duct combined with periportal fibrosis, and necrosis: (A) hematoxylin & eosin stain (800×); (B) Masson stain (1,600×).
Figure 3. Histopathologic examination of the tumor shows a trabec-
ular and acinar pattern, with the diagnosis of moderately differen-
tiated hepatocellular carcinoma (hematoxylin & eosin, 1,600×).
Figure 4. One month after radiofrequency ablation therapy, com-
puted tomography shows a hypoattenuating ablation zone without
enhancing portion in the early arterial phase (arrow).
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the risk factors that are associated with HCC in PBC
patients.10,12,15 Older age, male sex, a history of ciga-
rette smoking or blood transfusion, superimposition
of hepatitis C virus infection and advanced PBC stage
were significant risk factors.
This patient had positive anti-HBc in serum, indi-
cating past or ongoing occult HBV infection. Classically,
the seroclearance of HBsAg was considered to be asso-
ciated with favorable outcomes. Nevertheless, our pre-
vious study demonstrated that HBV viremia was
detected in 20% of patients who had seroclearance 
of HBsAg and the conversion of anti-HBs.16 More-
over, some patients with HBsAg seroclearance may
develop serious complications, including HCC.16 For
this patient, past exposure to HBV might also have
played a role in hepatocarcinogenesis in addition to
the underlying PBC.17
Surgical intervention was regarded as the only
curative modality for patients with HCC in the past.
Nowadays, several percutaneous local ablation thera-
pies, including ethanol injection (PEIT) and RFA, have
also been applied for the treatment of small HCC.
They both lead to promising outcomes in survival,
complete tumor necrosis and reduction of local tumor
recurrence.18–21 Notably, the long-term survival of
patients who underwent local ablation therapy was
comparable to that of patients who underwent surgi-
cal resection.20,21 Consequently, local ablation therapy
and surgery are both considered first-line options for
small HCC, especially for those less than 3 cm in diam-
eter.22 Compared to surgical resection, local ablation
therapies are safe, effective, less invasive and less expen-
sive. RFA seemed to result in a higher rate of total
tumor necrosis than PEIT.18,23 Hence, RFA has been
applied in a substantial number of patients with HCC
in recent years. However, the patients enrolled in pre-
vious studies chiefly had HCC secondary to viral hep-
atitis; experience with radiofrequency therapy for HCC
arising from PBC is very limited worldwide. As there
is ongoing improvement of diagnostic tools, both for
use in PBC and HCC, we believe that the number of
patients with HCC arising from PBC who are suitable
for curative therapy will soon increase. This report
demonstrates that RFA can successfully treat HCC 
in such patients, although large-scale studies may be
needed for confirmation.
Based on previous studies and our case report,
HCC can occur at any stage of PBC. All patients with
PBC, irrespective of stage, should receive regular sur-
veillance for HCC, including serum AFP and abdom-
inal ultrasound examination, during their lifetime. If
small HCC is detected at an early PBC stage when
there is still good liver reserve, then curative therapy
modalities including surgical resection and local abla-
tion therapy can be performed and long-term survival
expected.
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